Bahadır Koylu

Istanbul, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer.

Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 18, 2026

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

Journal: Journal of clinical medicine

Published: June 24, 2026

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 14, 2026

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Journal: Clinical genitourinary cancer

Published: May 03, 2026

Early Achievement of Ultra-low PSA Levels Correlates With Prolonged Radiologic Progression-free Survival (rPFS) in Metastatic Hormone-sensitive Prostate Cancer (mHSPC).

Early Achievement of Ultra-low PSA Levels Correlates With Prolonged Radiologic Progression-free Survival (rPFS) in Metastatic Hormone-sensitive Prostate Cancer (mHSPC).

Journal: Clinical genitourinary cancer

Published: April 14, 2026

Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Genes, chromosomes & cancer

Published: March 30, 2026

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.

Journal: Immunotherapy

Published: March 28, 2026

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Journal: JCO global oncology

Published: March 26, 2026

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.

Journal: Current oncology (Toronto, Ont.)

Published: March 11, 2026

Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study.

Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study.

Journal: Frontiers in oncology

Published: February 28, 2026

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Journal: International journal of cancer

Published: February 09, 2026

Showing 1-12 of 36

Last Updated: 09/26/2026